Cure Alzheimer s Fund Surpasses $125 Million In Research Funding prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
(0)
TORONTO and CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWIRE) ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced the appointment of Rudolph Tanzi, Ph.D, as Chair of the Company s scientific advisory board (SAB). Dr. Tanzi is the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard University and Vice-Chair of Neurology, Director of the Genetics and Aging Research Unit, and Co-Director of the Henry and Allison McCance Center for Brain Health at Massachusetts General Hospital.
Aerosmith s Joe Perry To Take Part In Vatican Conference On Covid 19 And Other Global Health Threats blabbermouth.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from blabbermouth.net Daily Mail and Mail on Sunday newspapers.
Thomson Reuters
But the drug missed most of the secondary trial goals, including one watched by experts.
An Eli Lilly executive told Insider the data was mixed, but very exciting.
The latest test of Eli Lilly s Alzheimer s disease drug ended with a mixed bag of results that disappointed investors.
Lilly gave an in-depth look at the performance of its drug, called donanemab, on Saturday at the International Conference on Alzheimer s and Parkinson s Diseases. The drug met the trial s primary goals, reducing a harmful substance that builds up in the brains of patients with Alzheimer s disease. It also slowed down the rate of cognitive decline by 32%, according to data published Saturday in a medical journal. But it missed the mark on several secondary tests.
As we age, we occasionally find ourselves questioning the cognitive abilities of ourselves or our loved ones. Researchers have recently shown that we can implement simple, everyday practices to potentially forestall the onset of Alzheimer’s and other related forms of dementia.
“Everyone is afraid of the ‘A’ word: Alzheimer’s,” says
Dr. Gayatri Devi, Director of Park Avenue Neurology in New York City. “The story always is that there s nothing that can be done for Alzheimer’s, nothing that can be done for dementia.” Dr. Devi emphasizes that each of us can implement positive lifestyle changes in order to make a difference. “There are many things you can do about dementia and Alzheimer s that are effective and available now to help change your life story going forward.”